PURA - Puration Announces New CBD Beverage TranquiliTeaCBD
September 24 2019 - 9:21AM
InvestorsHub NewsWire
PURA - Puration Announces New CBD
Beverage TranquiliTeaCBD
- Survey Includes
Analyst Confirm of PURA Spec BUY and $0.25 Target
- PURA Plans
Additional Corporate Announcements Coming This Week
- CBD Extract and
Flavor Profiles Already Developed
- First of Three New
CBD Beverages – Coffee and Beer to Follow
DALLAS, TX -- September 24, 2019 -- InvestorsHub NewsWire --
Puration, Inc. (PURA)
today announced a new CBD infused beverage, TranquiliTeaCBD.
The new product announcement today is the first of a series of
corporate releases coming from PURA this week. The series of
corporate releases scheduled for this week follow PURA’s CBD beverage industry
survey results and corresponding analyst research update
published last week in conjunction with PURA’s pre-marketing
initiative for its new CBD infused beer, coffee and tea. PURA
recently entered into a select number of partnerships with third
party producers of beer, coffee and tea with the intention of
producing CBD versions of all three. As a result of the survey
results, which indicated consumers primary interest in consuming
CBD was for the treatment of anxiety and that the preferred
beverage for consuming infused CBD was tea, PURA has decided to
lead with its new beverage announced today, TranquiliTeaCBD.
A CBD extract has already been developed and flavor profiles are
also developed. A logo (the image here is only a temporary
representation of the beverage’s name) and label are in the works
and expected to be complete within the next thirty days.
TranquiliTeaCBD is on track to be available for sale to consumers
by year end.
www.tranquiliTeaCBD.com
PURA Existing CBD Beverage Sales Growing Rapidly
Targeting $4 Million For 2019
PURA is an experienced CBD infused beverage producer. The
company’s maiden CBD beverage, EVERx CBD Sports Water, was
officially launched for the first time ever at Arnold
Schwarzenegger’s Arnold Classic in Columbus, Ohio in 2017.
EVERx today is the leading CBD infused sports nutrition beverage
with over $1 million in sales in 2018 and over $1 million in sales
in the first six months of 2019 and targeting $4 million in sales by 2019 year
end.
More News Coming This Week – Update To $0.25 Analyst
Target and Latest on Dividend
In addition to this new product announcement today, PURA has
plans for a series of additional releases throughout the week
covering new sales, its European marketing campaign, and new
products among other strategic updates. Management plans to
include in the announcements this week the latest news on the
progress toward issuing the previously announced dividend of
Nouveau (USOTC:
NOUV) stock to PURA shareholders. The scheduled corporate
releases will also include a further Research Analysis update on
PURA from Goldman Small Cap Research. The aforementioned CBD
survey was conducted by Goldman Small Cap Research and included a
confirmation of Goldman’s previous Speculative BUY and $0.25 PPS
Target for PURA. Goldman plans to publish a more comprehensive
update later this week including analysis of additional aspects of
PURA’s expanding operations on top of the survey driven analysis
update issued last week.
EVERx CBD Sports Water is available for purchase on line at
www.USMJ.com hosted by PURA’s partner North American
Cannabis Holdings, Inc. (USOTC:
USMJ). PURA plans for its new TranquiliTEACBD to also be
on sale at www.USMJ.com before the end of this year.
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Sep 2023 to Sep 2024